13D Filing: Broadfin Capital and Novelion Therapeutics Inc. (NVLN)

Page 5 of 9 – SEC Filing

CUSIP No. 67001K202
Item 1. Security and Issuer.
This statement on Schedule 13D (the “Schedule 13D”) relates to the Common Shares, without par value (the “Common Shares”), of Novelion Therapeutics Inc., a corporation incorporated under the laws of British Columbia with its principal executive offices located at 1800-510 West Georgia Street, Vancouver, British Columbia, Canada V6B 0M3 (the “Issuer”).
Item 2. Identity and Background.
(a)-(c), (f)

This Schedule 13D is being filed jointly by (i) Broadfin Capital,
LLC, a Delaware limited liability company, (ii) Broadfin Healthcare Master Fund, Ltd., an exempted company incorporated and existing
under the laws of the Cayman Islands, and (iii) Kevin Kotler, a United States citizen (collectively, the “Reporting Persons”).

The principal business address of the Reporting Persons is 300 Park
Avenue, 25th Floor, New York, New York 10022.

Kevin Kotler is the managing member of Broadfin Capital, LLC, an
investment management firm that serves as the investment manager to Broadfin Healthcare Master Fund, Ltd.  The principal
business of Broadfin Healthcare Master Fund, Ltd. is purchasing, holding and selling securities for investment purposes.

(d) None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.
Item 3. Source and Amount of Funds or Other Consideration.

The funds for the purchase of the Shares beneficially owned by the
Reporting Persons came from the working capital of Broadfin Healthcare Master Fund, Ltd.

No borrowed funds were used to purchase the Shares, other than any
borrowed funds used for working capital purposes (including certain leverage arrangements) in the ordinary course of business.

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)